Clinical and pharmacological group: & nbsp
Metabolics
Included in the formulation
АТХ:A.05.B.A Preparations for the treatment of liver diseases
Pharmacodynamics:Involved in the synthesis of phospholipids of cell membranes as a donor of methyl groups, it is used as construction material for proteinaceous compounds.
Bytransulfation is converted into thiol compounds: glutathione, taurine, cysteine, which participate in the processes of oxidation-reduction reaction.
The decarboxylation reaction is transformed into a precursor of polyamines providing regeneration and proliferation of hepatocytes.
Pharmacokinetics:Not specified.
Indications:It is used to treat chronic non-calculous cholecystitis, cholangitis, intrahepatic cholestasis, fatty liver, hepatic encephalopathy, withdrawal syndrome.
IV.E50-E64.E64.0 Consequences of protein-energy deficiency
XI.K70-K77.K71 Toxic liver disease
XI.K70-K77.K74 Fibrosis and cirrhosis of the liver
XI.K70-K77.K76.0 Fatty degeneration of the liver, not elsewhere classified
XVIII.R50-R69.R64 Cachexia
Contraindications:Viral hepatitis, severe hepatic insufficiency.
Individual intolerance.
Pregnancy and lactation:Recommendations for FDA - Category B. It is used during pregnancy and lactation.
Dosing and Administration:Application in children
Inside, up to 1 year: 100 mg;
1-2 years: 200 mg;
2-4 years: 250 mg;
4-6 years: 300 mg;
7-18 years: 500 mg.
Adults
Inside, 0.5-1.5 g 3-4 times a day, half an hour before meals for 10-30 days.
The highest daily dose: 4 g.
The highest single dose: 1.5 g.
Side effects:Nausea, vomiting, irritability.
Allergic reactions.
Overdose:Arrhythmia, disorientation, lowering blood pressure.
Treatment is symptomatic.
Interaction:With simultaneous use reduces the therapeutic effects of levodopa.
Special instructions:It is recommended to take the drug in combination with other amino acids. Increased doses of methionine can have a damaging effect on hepatocytes and cells of other internal organs.